Chemotherapy for Metastatic Colorectal Cancer

View More View Less
  • 1 Division of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA

The past decade has seen a significant survival improvement for patients with metastatic colorectal cancer, fueled in large part by the arrival of active novel chemotherapeutic drugs and their incorporation into combination regimens. Several randomized trials have successfully integrated oxaliplatin and irinotecan into previously existing 5-fluorouracil (5-FU)-based regimens for advanced colorectal cancer, resulting in median survivals that have risen from 9 months to almost 2 years. Even as the ideal combinations and sequences of these regimens are elucidated, targeted therapies such as recently approved bevacizumab and cetuximab have been added to treatment protocols, with favorable consequences. We review the evolution of primary chemotherapy for advanced colorectal cancer, focusing on the trials that have led to the new standard first-line treatments. We also review the data on newer targeted therapies, especially in combination with cytotoxic therapy.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Lucille A. Leong, MD, Division of Medical Oncology and Therapeutics Research, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010. Email: lleong@coh.org
  • 1

    Poon MA, O'Connell MJ, Wieand HS. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:19671972.

    • Search Google Scholar
    • Export Citation
  • 2

    Petrelli N, Herrera L, Rustum Y. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:15591565.

    • Search Google Scholar
    • Export Citation
  • 3

    de Gramont A, Bosset C, Milan C. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997;15:808815.

    • Search Google Scholar
    • Export Citation
  • 4

    Van Cutsem E, Twelves C, Cassidy J. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:40974106.

    • Search Google Scholar
    • Export Citation
  • 5

    Van Cutsem E, Hoff PM, Harper P. Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials. Br J Cancer 2004;90:11901197.

    • Search Google Scholar
    • Export Citation
  • 6

    Saltz LB, Cox JV, Blanke C. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905914.

    • Search Google Scholar
    • Export Citation
  • 7

    Rothenberg ML, Meropol NJ, Poplin EA. Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel. J Clin Oncol 2001:19:38013807.

    • Search Google Scholar
    • Export Citation
  • 8

    Andre T, Louvet C, Maindrault-Goebel F. CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer. GERCOR. Eur J Cancer 1999;35:13431347.

    • Search Google Scholar
    • Export Citation
  • 9

    Douillard J, Cunningham D, Roth A. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:10411047.

    • Search Google Scholar
    • Export Citation
  • 10

    Levi F, Perpoint B, Garufi C. Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 1993;29A:12801284.

    • Search Google Scholar
    • Export Citation
  • 11

    Levi F, Misset JL, Brienza S. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer. Cancer 1992;69:893900.

    • Search Google Scholar
    • Export Citation
  • 12

    Goldberg RM, Sargent DJ, Morton RF. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:2330.

    • Search Google Scholar
    • Export Citation
  • 13

    Maindrault-Goebel F, Louvet C, Andre T. Oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX6). GERCOR. Eur J Cancer 1999;35:13381342.

    • Search Google Scholar
    • Export Citation
  • 14

    de Gramont A, Cervantes A, Andre T. OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. ASCO Annual Meeting Proceedings. J Clin Oncol 2004;22(14S):3525.

    • Search Google Scholar
    • Export Citation
  • 15

    Hurwitz H, Fehrenbacher L, Novotny W. Bevacizumab plus irinotecan, Fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:23352342.

    • Search Google Scholar
    • Export Citation
  • 16

    Giantonio BJ, Catalano PJ, Meropol NJ. High-dose bevacizumab in combination with FOLFOX4 improves survival in patients with previously treated advanced colorectal cancer: Results from the Eastern Cooperative Oncology Group (ECOG) study E3200 (Abstr 169a.). Presentation. GI ASCO 2005.

    • Search Google Scholar
    • Export Citation
  • 17

    Hochster HS, Welles L, Hart L. Bevacizumab (B) with oxaliplatin (O)-based chemotherapy in the first-line therapy of metastatic colorectal cancer (mCRC): Preliminary results of the randomized “TREE-2” trial (Abstr #241). Presentation. GI ASCO 2005.

    • Search Google Scholar
    • Export Citation
  • 18

    Tournigand C, Andre T, Achille E. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229237.

    • Search Google Scholar
    • Export Citation
  • 19

    Cunningham D, Humblet Y, Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337345.

    • Search Google Scholar
    • Export Citation
  • 20

    Saltz LB, Lenz H, Kindler H. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer (Abstr #169b). Presentation. GI ASCO 2005.

    • Search Google Scholar
    • Export Citation
  • 21

    Kemeny MM, Adak S, Gray B. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy – an intergroup study. J Clin Oncol 2002;20:14991505.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 88 26 1
PDF Downloads 38 20 1
EPUB Downloads 0 0 0